Ma, F., Luo, S., Zhang, B., Ma, Q., Ji, S., Zhang, Z., Zhang, Y., Yang, W., Peng, L., Guo, D., Ren, J., Zhang, Y., Su, Y., Li, J., Liu, W., Huang, J., Yuan, W. (2025). PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.406